18F-THK523: a novel in vivo tau imaging ligand for Alzheimer's disease.
Michelle T Fodero-Tavoletti, Nobuyuki Okamura, Shozo Furumoto, Rachel S Mulligan, Andrea R Connor, Catriona A McLean, Diana Cao, Angela Rigopoulos, Glenn A Cartwright, Graeme O'Keefe, Sylvia Gong, Paul A Adlard, Kevin J Barnham, Christopher C Rowe, Colin L Masters, Yukitsuka Kudo, Roberto Cappai, Kazuhiko Yanai, Victor L Villemagne
Brain | Published : 2011
While considerable effort has focused on developing positron emission tomography β-amyloid imaging radiotracers for the early diagnosis of Alzheimer's disease, no radiotracer is available for the non-invasive quantification of tau. In this study, we detail the characterization of (18)F-THK523 as a novel tau imaging radiotracer. In vitro binding studies demonstrated that (18)F-THK523 binds with higher affinity to a greater number of binding sites on recombinant tau (K18Δ280K) compared with β-amyloid(1-42) fibrils. Autoradiographic and histofluorescence analysis of human hippocampal serial sections with Alzheimer's disease exhibited positive THK523 binding that co-localized with immunoreactive..View full abstract